Padsevonil
Anticonvulsant drug
| Padsevonil | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Padsevonil is an investigational anticonvulsant drug developed for the treatment of epilepsy. It is designed to target both synaptic vesicle protein 2A (SV2A) and the GABAergic system, offering a novel mechanism of action compared to existing antiepileptic drugs.
Mechanism of Action[edit]
Padsevonil acts by binding to the SV2A protein, which is involved in the regulation of neurotransmitter release in the brain. This binding is thought to modulate synaptic transmission and reduce the frequency of seizures. Additionally, Padsevonil enhances the activity of the GABAergic system, which is the primary inhibitory neurotransmitter system in the central nervous system. By enhancing GABAergic inhibition, Padsevonil helps to stabilize neuronal activity and prevent the excessive neuronal firing that characterizes epileptic seizures.
Pharmacokinetics[edit]
The pharmacokinetic profile of Padsevonil includes rapid absorption and a moderate half-life, allowing for convenient dosing schedules. It is metabolized primarily in the liver and excreted through the kidneys. The drug's pharmacokinetics are designed to provide consistent therapeutic levels with minimal fluctuations, reducing the risk of breakthrough seizures.
Clinical Trials[edit]
Padsevonil has undergone several phases of clinical trials to evaluate its efficacy and safety in patients with drug-resistant epilepsy. These trials have demonstrated that Padsevonil can significantly reduce seizure frequency in patients who have not responded to other treatments. The drug is generally well-tolerated, with the most common side effects being dizziness, somnolence, and headache.
Development and Future Directions[edit]
Padsevonil is being developed by UCB Pharma, a company with a strong focus on neurological disorders. The drug represents a promising addition to the arsenal of treatments available for epilepsy, particularly for patients with drug-resistant forms of the condition. Ongoing research is focused on optimizing dosing regimens and exploring the potential of Padsevonil in other neurological disorders.
Related pages[edit]
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99 with insurance
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
